Inhibition of bromodomain and extra‐terminal proteins increases sensitivity to venetoclax in chronic lymphocytic leukaemia

The development of drugs able to target BTK, PI3k‐delta and BCL2 has dramatically improved chronic lymphocytic leukaemia (CLL) therapies. However, drug resistance to these therapies has already been reported due to non‐recurrent changes in oncogenic pathways and genes expression signatures. In this...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Cell Mol Med
Autors principals: Carrà, Giovanna, Nicoli, Paolo, Lingua, Marcello Francesco, Maffeo, Beatrice, Cartellà, Antonio, Circosta, Paola, Brancaccio, Mara, Parvis, Guido, Gaidano, Valentina, Guerrasio, Angelo, Saglio, Giuseppe, Taulli, Riccardo, Morotti, Alessandro
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2019
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6991693/
https://ncbi.nlm.nih.gov/pubmed/31821686
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.14857
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars